Back to results
US 10,246,510 B2Granted
KIR3DL2 binding agents
AssigneeInnate Pharma
InventorsLaurent Gauthier, Benjamin Rossi, Hélène Sicard, Carine Paturel
Life of this patent
Estimating the term…
Abstract
The present invention relates to methods for the treatment of cancer and inflammatory disease using antibodies (e.g. monoclonal antibodies), antibody fragments, and derivatives thereof that specifically bind KIR3DL2. The invention also relates to antibodies, cells producing such antibodies; methods of making such antibodies; fragments, variants, and derivatives of the antibodies; pharmaceutical compositions comprising the same.
Claims20
An isolated monoclonal antibody selected from the group consisting of:
- (a) a monoclonal antibody having (i) a heavy chain comprising CDR 1, 2 and 3 (HCDR1, HCDR2, HCDR3) comprising a sequence of SEQ ID NO:
- 4 (HCDR1), SEQ ID NO:
- 7 (HCDR2) and SEQ ID NO:
- 9 (HCDR3), respectively, and (ii) a light chain comprising CDR 1, 2 and 3 (LCDR1, LCDR2, LCDR3) comprising a sequence of SEQ ID NO:
- 10, 11 and 12, respectively;
- (b) a monoclonal antibody having (i) a heavy chain comprising CDR 1, 2 and 3 (HCDR1, HCDR2, HCDR3) comprising a sequence of SEQ ID NO:
- 15 (HCDR1), SEQ ID NO:
- 18 (HCDR2) and SEQ ID NO:
- 20 (HCDR3) respectively, and (ii) a light chain comprising CDR 1, 2 and 3 (LCDR1, LCDR2, LCDR3) comprising a sequence of SEQ ID NO:
- 21, 22 and 23, respectively;
- (c) a monoclonal antibody having (i) a heavy chain comprising CDR 1, 2 and 3 (HCDR1, HCDR2, HCDR3) comprising a sequence of SEQ ID NO:
- 16 (HCDR1), SEQ ID NO:
- 18 (HCDR2) and SEQ ID NO:
- 28 (HCDR3), respectively, and (ii) a light chain comprising CDR 1, 2 and 3 (LCDR1, LCDR2, LCDR3) comprising a sequence of SEQ ID NO:
- 29, 30 and 31, respectively;
- (d) a monoclonal antibody having (i) a heavy chain comprising CDR 1, 2 and 3 (HCDR1, HCDR2, HCDR3) comprising a sequence of SEQ ID NO:
- 26 (HCDR1), SEQ ID NO:
- 36 (HCDR2) and SEQ ID NO:
- 38 (HCDR3), respectively, and (ii) a light chain comprising CDR 1, 2 and 3 (LCDR1, LCDR2, LCDR3) comprising a sequence of SEQ ID NO:
- 39, 40 and 41, respectively;
- (e) a monoclonal antibody having (i) a heavy chain comprising CDR 1, 2 and 3 (HCDR1, HCDR2, HCDR3) comprising a sequence of SEQ ID NO:
- 16 (HCDR1), SEQ ID NO:
- 36 (HCDR2) and SEQ ID NO:
- 38 (HCDR3), respectively, and (ii) a light chain comprising CDR 1, 2 and 3 (LCDR1, LCDR2, LCDR3) comprising a sequence of SEQ ID NO:
- 44, 45 and 41, respectively;
- and
- (f) a monoclonal antibody having (i) a heavy chain comprising CDR 1, 2 and 3 (HCDR1, HCDR2, HCDR3) comprising a sequence of SEQ ID NO:
- 48 (HCDR1), SEQ ID NO:
- 51 (HCDR2) and SEQ ID NO:
- 53 (HCDR3), respectively, and (ii) a light chain comprising CDR 1, 2 and 3 (LCDR1, LCDR2, LCDR3) comprising a sequence of SEQ ID NO:
- 54, 55 and 56, respectively.
28 more elements
A method for the treatment of a KIR3DL2-expressing CD4+ T cell cancer in a patient in need thereof, the method comprising administering to said patient an effective amount of a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a monoclonal antibody selected from the group consisting of:
- (a) a monoclonal antibody having (i) a heavy chain comprising CDR 1, 2 and 3 (HCDR1, HCDR2, HCDR3) comprising a sequence of SEQ ID NO:
- 4 (HCDR1), SEQ ID NO:
- 7 (HCDR2) and SEQ ID NO:
- 9 (HCDR3), respectively, and (ii) a light chain comprising CDR 1, 2 and 3 (LCDR1, LCDR2, LCDR3) comprising a sequence of SEQ ID NO:
- 10, 11 and 12, respectively;
- (b) a monoclonal antibody having (i) a heavy chain comprising CDR 1, 2 and 3 (HCDR1, HCDR2, HCDR3) comprising a sequence of SEQ ID NO:
- 15 (HCDR1), SEQ ID NO:
- 18 (HCDR2) and SEQ ID NO:
- 20 (HCDR3), respectively, and (ii) a light chain comprising CDR 1, 2 and 3 (LCDR1, LCDR2, LCDR3) comprising a sequence of SEQ ID NO:
- 21, 22 and 23, respectively;
- (c) a monoclonal antibody having (i) a heavy chain comprising CDR 1, 2 and 3 (HCDR1, HCDR2, HCDR3) comprising a sequence of SEQ ID NO:
- 16 (HCDR1), SEQ ID NO:
- 18 (HCDR2) and SEQ ID NO:
- 28 (HCDR3), respectively, and (ii) a light chain comprising CDR 1, 2 and 3 (LCDR1, LCDR2, LCDR3) comprising a sequence of SEQ ID NO:
- 29, 30 and 31, respectively;
- (d) a monoclonal antibody having (i) a heavy chain comprising CDR 1, 2 and 3 (HCDR1, HCDR2, HCDR3) comprising a sequence of SEQ ID NO:
- 26 (HCDR1), SEQ ID NO:
- 36 (HCDR2) and SEQ ID NO:
- 38 (HCDR3), respectively, and (ii) a light chain comprising CDR 1, 2 and 3 (LCDR1, LCDR2, LCDR3) comprising a sequence of SEQ ID NO:
- 39, 40 and 41, respectively;
- (e) a monoclonal antibody having (i) a heavy chain comprising CDR 1, 2 and 3 (HCDR1, HCDR2, HCDR3) comprising a sequence of SEQ ID NO:
- 16 (HCDR1), SEQ ID NO:
- 36 (HCDR2) and SEQ ID NO:
- 38 (HCDR3), respectively, and (ii) a light chain comprising CDR 1, 2 and 3 (LCDR1, LCDR2, LCDR3) comprising a sequence of SEQ ID NO:
- 44, 45 and 41, respectively;
- and
- (f) a monoclonal antibody having (i) a heavy chain comprising CDR 1, 2 and 3 (HCDR1, HCDR2, HCDR3) comprising a sequence of SEQ ID NO:
- 48 (HCDR1), SEQ ID NO:
- 51 (HCDR2) and SEQ ID NO:
- 53 (HCDR3), respectively, and (ii) a light chain comprising CDR 1, 2 and 3 (LCDR1, LCDR2, LCDR3) comprising a sequence of SEQ ID NO:
- 54, 55 and 56, respectively.
28 more elements
Dependencies are inferred from the claim text.